Liposomal nanocarriers for tumor imaging

Journal of Biomedical Nanotechnology

Volumn 5, Issue 2, 2009, Pages 141-150

  Erdogan, Suna ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Computed tomography (CT); Liposome; Magnetic resonance imaging (MRI); Scintigraphic imaging; Tumor imaging; Ultrasonography

Indexed keywords

AREA OF INTEREST; CANCER IMAGING; COMPUTED TOMOGRAPHY; COMPUTED TOMOGRAPHY (CT); DRUG CARRIER; IMAGING MODALITY; LIPOSOMAL NANOCARRIERS; NANOCARRIERS; NANOMEDICINE; SCINTIGRAPHIC IMAGING; TUMOR IMAGING;

COMPUTERIZED TOMOGRAPHY; HISTOLOGY; LIPOSOMES; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; MEDICAL NANOTECHNOLOGY; ONCOLOGY; PHOSPHOLIPIDS; TUMORS; ULTRASONIC IMAGING; ULTRASONOGRAPHY;

TOMOGRAPHY;

3' FLUOROTHYMIDINE F 18; ALBUNEX; BIOTIN TC 99M; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GALLIUM 67; IODINATED CONTRAST MEDIUM; IODINATED LIPOSOME; IODINE; IODIXANOL; IOMEPROL; LIPOSOMAL IODINE; LIPOSOMAL IODIXANOL; LIPOSOMAL IOMEPROL; LIPOSOMAL NANOCARRIER; LIPOSOME; LIPOSOME I; LIPOSOME IN 111; LIPOSOME TC 99M; MACROGOL; NANOBUBBLE; NANOCARRIER; NANOSCALE LIPOSOME; PEGYLATED LIPOSOME; PENTETIC ACID; PERFLUTREN; RADIOPHARMACEUTICAL AGENT; SONOVUE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL PEPTIDE TC 99M; VESCAN;

BREAST CANCER; CANCER SCINTISCANNING; COLORECTAL CANCER; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG UPTAKE; ECHOGRAPHY; HUMAN; IMAGING SYSTEM; ISOTOPE LABELING; LIPID VESICLE; LIPOSOMAL DELIVERY; MAGNETIC FIELD; MOLECULAR IMAGING; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RETICULOENDOTHELIAL SYSTEM; REVIEW; SCINTIGRAPHY; SIGNAL PROCESSING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMACH CANCER;

ANIMALS; CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS; IMAGE ENHANCEMENT; LIPOSOMES; NEOPLASMS;

EID: 67649306860     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2009.1016     Document Type: Review

References (97)

1. V. P. Torchilin, Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58, 1532 (2006).
2. R. Saito, J. R. Bringas, T. R. McKnight, M. F. Wendland, C. Mamot, D. C. Drummond, D. B. Kirpotin, J. W. Park, M. S. Berger, and K. S. Bankiewicz, Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 64, 2572 (2004).
3. U. M. Le and Z. Cui, Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy. Int. J. Pharm. 320, 96 (2006).
4. L. Frich, A. Bjørnerud, S. Fossheim, T. Tillung, and I. Gladhaug, Experimental application of thermosensitive paramagnetic liposomes for monitoring magnetic resonance imaging guided thermal ablation. Magn. Reson. Med. 52, 1302 (2004).
5. D. D. Lasic (ed.), Liposomes from Physics to Applications, Elsevier, Amsterdam (1993).
6. R. R. C. New (ed.), Liposomes a Practical Approach, Oxford University Press, New York (1990).
7. O. Gregoriadis (ed.), Liposome Technology, Informa Healthcare, New York (2007), Vols. 1-3.
8. Y. Yamada, H. Akita, K. Kogure, H. Kamiya, and H. Harashima, Mitochondrial drug delivery and mitochondrial disease therapy-an approach to liposome-based delivery targeted to mitochondria. Mitochondrion 7, 63 (2007).
9. S. V. Boddapati, G. G. D'Souza, S. Erdogan, V. P. Torchilin, and V. Weissig, Organelle-targeted nanocarriers: Specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett. 8, 2559 (2008).
10. W. T. Al-Jamal, K. T. Al-Jamal, P. H. Bomans, P. M. Frederik, and K. Kostarelos, Functionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancer. Small 4, 1406 (2008).
11. J. Huwyler, J. Drewe, and S. Krähenbuhl, Tumor targeting using liposomal antineoplastic drugs. Int. J. Nanomedicine. 3, 21(2008).
12. V. P. Torchilin, Liposomes as delivery agents for medical imaging. Mol. Med. Today 2, 242 (1996).
13. V. P. Torchilin, Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS Journal 9, E128 (2007).
14. V. P. Torchilin, Drug targeting. Eur. J. Pharm. Sci. 11(Suppl 2), S81 (2000).
15. P. Sapra, P. Tyagi, and T. M. Allen, Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2, 369 (2005).
16. H. Maeda, T. Sawa, and T. Konno, Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 74, 47 (2001).
17. S. K. Hobbs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, and R. K. Jam, Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 95, 4607 (1998).
18. G. B. Saha, Instruments for Radiation and Measurement, in Fundamentals of Nuclear Pharmacy, edited by G. B. Saha, Springer, New York (2003), pp. 31-45.
19. D. J. Hnatowich, B. Friedman, B. Clancy, and M. Novak, Labeling of preformed liposomes with Ga-67 and Tc-99m by chelation. J. Nucl. Med. 22, 810 (1981).
20. I. K. Adzamli, S. E. Seltzer, M. Slifkin, M. Blau, and D. F. Adams, Production and characterization of improved liposomes containing radiographic contrast media. Invest. Radiol. 25, 1217 (1990).
21. S. Erdogan, A. Y. Ozer, M. T. Ercan, and A. A. Hincal, In vivo studies on radiopaque niosomes. STP Pharma Sci. Ed. 6, 87 (1996).
22. S. Turker, S. Erdogan, A. Y. Ozer, E. L. Ergun, M. Tuncel, H. Bilgili, and S. Deveci, Scintigraphic imaging of radiolabelled drug delivery systems in rabbits with arthritis. Int. J. Pharm. 296, 34 (2005).
23. IIIIn-labeled polychelating-polymer- containing immunoliposomes. Mol. Pharm. 3, 525 (2006).
24. T. Elbayoumi and V. P. Torchilin, Enhanced toxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur. J. Pharm. Sci. 32, 159 (2007).
25. S. Erdogan, A. Y. Ozer, M. T. Ercan, and A. A. Hincal, Scintigraphic imaging of infections with 99m-Tc labelled glutathione liposomes. J. Microencap. 17, 459 (2000).
26. W. T. Phillips, A. S. Rudolph, B. Goins, J. H. Timmons, R. Klipper, and R. Blumhardt, A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Nucl. Med. Biol. 19, 539 (1992).
27. M. Suresh and Y. Cao, A simple and efficient method for radiolabeling of preformed liposomes. J. Pharm. Pharm. Sci. 1, 31 (1998).
28. M. Jaggi, R. Khar, U. Chauhan, and S. Gangal, Liposomes as carriers of technetium-99m glucoheptonate for liver imaging. Int. J. Pharm. 69, 77 (1991).
29. M. L. Immordino, F. Dosio, and L. Cattel, Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine. 1, 297 (2006).
30. V. P. Torchilin, Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145 (2005).
31. S. K. Huang, K. D. Lee, K. Hong, D. S. Friend, and D. Papahadjopoulos, Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52, 5135 (1992).
32. H. Maeda, The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189 (2001).
33. 111In-NTA: Biodistribution in mice. J. Nucl. Med. 24, 45 (1983).
34. K. R. Patel, G. W. Tin, L. E. Williams, and J. D. Baldeschwieler, Biodistribution of phospholipid vesicles in mice bearing Lewis lung carcinoma and granuloma. J. Nucl. Med. 26, 1048 (1985).
35. A. F. Turner, C. A. Presant, R. T. Proffitt, L. E. Williams, D. W. Winsor, and J. L. Werner, In-111-labeled liposomes: Dosimetry and tumor depiction. Radiology 166, 761 (1988).
36. C. A. Presant, A. F. Turner, and R. T. Proffitt, Potential for improvement in clinical decision-making: Tumor imaging with In-111 labeled liposomes. Results of a phase II-III study. J. Lip. Res. 4, 985 (1994).
37. H. Gupta and R. Weissleder, Targeted contrast agents in MR imaging. Magn. Reson. Imaging Clin. N. Am. 4, 171 (1996).
38. K. J. Harrington, M. Mubashar, and A. M. Peters, Polyethylene glycol in the design of tumor-targetting radiolabelled macromolecules-lessons from liposomes and monoclonal antibodies. Q. J. Nucl. Med. 46, 171 (2002).
39. A. M. Morawski, G. A. Lanza, and S. A. Wickline, Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr. Opin. BiotechnoL 16, 89 (2005).
40. V. P. Torchilin, Polymeric contrast agents for medical imaging. Curr Pharm. Biotechnol. 1, 183 (2000).
41. Y. M. Zhang, M. Rusckowski, N. Liu, C. Liu, and D. J. Hnatowich, Cationic liposomes enhance cellular/nuclear localization of 99mTc-antisense oligonucleotides in target tumor cells. Cancer Biother Radiopharm. 16, 411(2001).
42. S. Dagar, A. Krishnadas, I. Rubinstein, M. J. Blend, and H. Onyuksel, VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer In vivo studies. J. Control Rel. 91, 123 (2003).
43. W. T. Phillips, L. A. Medina, R. Klipper, and B. Goins, A novel approach for the increased delivery of pharmaceutical agents to peritoneum and associated lymph nodes. J. Pharmacol. Exp. Ther. 303, 11(2002).
44. N. Oku, Delivery of contrast agents for positron emission tomography imaging by liposomes. Adv. Drug Deliv. Rev. 37, 53 (1999).
45. R. J. Hicks, Beyond FDG: Novel PET tracers for cancer imaging. Cancer Imaging 4, 22 (2003).
46. L. W. R. S. Goldman, Principles of CT and CT technology. J. NucL Med. Technol. 35, 115 (2007).
47. J. H. Senior, Fate and behaviour of liposomes in vivo: A review of controlling factors. CRC Crit. Rev. Ther Drug Carrier Syst. 3, 123 (1987).
48. P. Leander, P. Hoglund, A. Borseth, Y. Kloster, and A. Berg, A new liposomal liver specific contrast agent for CT: First human Phase I clinical trial assessing efficacy and safety. Eur. Radiol. 11, 698 (2001).
49. A. Sachse, J. U. Leike, O. L. Rössling, S. E. Wagner, and W. Krause, Preparation and evaluation of lyophilized iopromide-carrying liposomes for liver tumor detection. Invest. Radiol. 28, 838 (1993).
50. X. Fouillet, H. Tournier, H. Khan, S. Sabitha, S. Burkhardt, F. Terrier, and M. Schneider, Enhancement of computed tomography liver contrast using iomeprol-containing liposomes and detection of small liver tumors in rats. Acad. Radiol. 2, 576 (1995).
51. A. Sachse, J. U. Leike, T. Schneider, S. Wagner, G. L. Rossling, W. Krause, and M. Brandl, Biodistribution and computed tomography blood-pool imaging properties of polyethylene glycol coated iopromide-carrying liposomes. Invest. Radiol. 32, 44 (1997).
52. T. S. Desser, D. L. Rubin, H. Muller, G. L. Mclntire, B. R. Bacon, and J. L. Toner, Blood pool and liver enhancement in CT with liposomal iodixanol: Comparison with iohexol. Acad. Radiol. 6, 176 (1999).
53. X. Wei, F. Geng, D. He, J. Qiu, and Y. Xu, Liposomal contrast agent for CT imaging of the liver. Proceedings of the 2005 IEEE Engineering in Medicine and Biology 27th Annual Conference, Shanghai, China, September (2005), pp. 5702-5705.
54. X. Montet, C. M. Pastor, J. P. Vallée, C. D. Becker, A. Geissbuhler, D. R. Morel, and P. Meda, Improved visualization of vessels and hepatic tumors by micro-computed tomography (CT) using iodinated liposomes. Invest. Radiol. 42, 652 (2007).
55. R. B. Clarkson, Blood-pool MRI contrast agents: Properties and characterization. Topics in Current Chemistry, Contrast Agent, edited by W. Krause, Springer-Verlag, Berlin Heidelberg (2002), Vol.221, pp. 202-235.
56. G. L. Wolf, Delivery of diagnostic agents: Achievements and challenges, Adv. Drug Delivery Rev. 37, 1 (1999).
57. V. P. Torchilin and V. S. Trubetskoy, Which polymers can make nanoparticulate drug carriers long-circulating? Adv. Drug Delivery Rev. 16, 141 (1995).
58. A. A. Gabizon, Liposome circulation time and tumor targeting: Implications for cancer chemotherapy. Adv. Drug Delivery Rev. 16, 285 (1995).
59. S. Erdogan, Z. O. Medarova, A. Roby, A. Moore, and V. P. Torchilin, Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. J. Mag. Res. Imag. 27, 574 (2008).
60. V. S. Trubetskoy and V. P. Torchilin, New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph node. J. Lip. Res. 4, 961 (1994).
61. V. V. Weissig, J. Babich, and V. P. Torchilin, Long-circulating gadoliniumloaded liposomes: Potential use for magnetic resonance imaging of the blood pool. Coll. Surf. B, Biointerfaces 18, 293 (2000).
62. A. Serres, M. Baudys, and S. W. Kim, Temperature and pH-sensitive polymers for human calcitonin delivery. Pharm. Rex. 13, 196 (1996).
63. K. Nakamura, Y. Maitani, A. M. Lowman, K. Takayama, and N. A. Peppas, Uptake and release of budesonide from mucoadhesive, pH-sensitive copolymers and their application to nasal delivery. J. Control. Rel. 61, 329 (1999).
64. K. E. Løklinga, S. L. Fossheimb, R. Skurtveitb, A. Bjømerudb, and J. Klavenessa, pH-sensitive paramagnetic liposomes as MRI contrast agents: In vitro feasibility studies. Magn. Reson. Imaging 19, 731 (2001).
65. N. Hazemoto, M. Harada, N. Komatsubara, M. Haga, and Y. Kato, pH sensitive liposomes composed of phosphatidylethanolamine and fatty acid. Chem. Pharm. Bull. (Tokyo) 38, 748 (1990).
66. J. W. Bulte, M. de Cuyper, D. Despres, and J. A. Frank, Preparation, relaxometry, and biokinetics of PEGylated magnetoliposomes as MR contrast agent. J. Magn. Magn. Mater 194, 204 (1999).
67. K. Morita, F. Zywietz, K. Kakinuma, R. Tanaka, and M. Katoh, Efficacy of doxorubicin thermosensitive liposomes (40 degrees C) and local hyperthermia on rat rhabdomyosarcoma. Oncol Rep. 20, 365 (2008).
68. N. McDannold, S. L. Fossheim, H. Rasmussen, H. Martin, N. Vykhodtseva, and K. Hynynen, Heat-activated liposomal MR contrast agent: Initial in vivo results in rabbit liver and kidney. Radiology 230, 743 (2004).
69. K. Kono, Thermosensitive polymer-modified liposomes. Adv. Drug Deliv. Rev. 53, 307 (2001).
70. S. L. Fossheim, K. A. Il'yasov, J. Hennig, and A. Bjornerud, Thermosensitive paramagnetic liposomes for temperature control during MR imaging-guided hyperthermia: In vitro feasibility studies. Acad. Radiol. 7, 1107 (2000).
71. J. W. Mulder, G. J. Strijkers, A. W. Griffloen, L. van Bloois, G. Molema, G. Storm, G. A. Koning, and K. Nicolay, A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjugate Chem. 15, 799 (2004).
72. A. M. Morawski, G. A. Lanza, and S. A. Wickline, Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr Opin. Biotechnol. 16, 89 (2005).
73. T. E. Herbener, Ultrasound physics: Principles of ultrasonography. Gastrointest. Endosc. 43, S4 (1996).
74. T. D. Case, Ultrasound physics and instrumentation. Surg. Clin. North Am. 78, 197 (1998).
75. A. P. Miller and N. C. Nanda, Contrast echocardiography: New agents, Ultrasound. Med. Biol. 30, 425 (2004).
76. M. A. Wheatley and S. Singhal, Structural studies on stabilized microbubbles: Development of a novel contrast agent for diagnostic ultrasound. Reactive Polymers 25, 157 (1995).
77. H. Alkan-Onyuksel, S. M. Demos, G. M. Lanza, M. J. Vonesh, M. B. Klegerman, B. J. Kane, J. Kuszak, and D. D. McPherson, Development of inherently echogenic liposomes as an ultrasonic contrast agent. J. Pharm. Sci. 85, 486 (1996).
78. R. Liu, X. Wei, Y. Yao, Q. Chai, Y. Chen, and Y. Xu, The preparation and characterization of gas bubble containing liposomes. Proceedings of the 2005 IEEE Engineering in Medicine and Biology 27th Annual Conference, Shanghai, China, September (2005), pp. 3998-4001.
79. S. B. Feinstein, F. J. Ten Cate, W. Zwehl, K. Ong, G. Maurer, C. Tei, P. M. Shah, S. Meerbaum, and E. Corday, Two dimensional contrast echocardiography. In vitro development and quantitative analysis of echo contrast agents. J. Am. Coll. Cardiol. 3, 14 (1984).
80. F. Calliada, R. Campani, O. Bottinelli, A. Bozzini, and M. G. Sommaruga, Ultrasound contrast agents Basic principles. Eur. J. Radiol. 27, S 157 (1998).
81. D. Cosgrove, Echo enhancers and ultrasound imaging. Eur. J. Radiol. 26, 64 (1997).
82. B. E. Oeffinger and M. A. Wheatley, Development and characterization of a nano-scale contrast agent. Ultrasonics 42, 343 (2004).
83. M. Schneider, Molecular imaging and ultrasound-assisted drug delivery. J. Endourol. 22, 1 (2008).
84. E. C. Unger, T. Porter, W. Culp, R. Labell, T. Matsunaga, and R. Zutshi, Therapeutic applications of lipid-coated microbubbles. Adv. Drug Deliv. Rev. 56, 1291 (2004).
85. M. Fechheimer, J. F. Boylan, S. Parker, J. B. Sisken, O. L. Patel, and S. G. Zimmer, Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading. Proc. Natl. Acad. Sci. USA 84, 8463 (1987).
86. M. W. Miller, D. L. Miller, and A. A. Brayman, A review of in vitro bioeffects of inertial ultrasonic cavitation from a mechanistic perspective. Ultrasound Med. Biol. 22, 1131 (1996).
87. M. Joersbo and J. Brunstedt, Protein synthesis stimulated in sonicated sugar beet cells and protoplasts. Ultrasound Med. Biol. 16, 719 (1990).
88. D. L. Miller, S. V. Pislaru, and J. B. Greenleaf, Sonoporation: Mechanical DNA delivery by ultrasonic cavitation. Somat. Cell Mol. Genet. 27, 115 (2002).
89. W. Wei, B. Zheng-Zhong, W. Yong-Jie, Z. Qing-Wu, and M. Ya-Lin, Bioeffects of low-frequency ultrasonic gene delivery and safety on cell membrane permeability control. J. Ultrasound Med. 23, 1569 (2004).
90. H. J. Kim, J. F. Greenleaf, R. R. Kinnick, J. T. Bronk, and M. E. Bolander, Ultrasound-mediated transfection of mammalian cells. Hum. Gene Ther. 7, 1339 (1996).
91. M. Duvshani-Eshet and M. Machluf, Therapeutic ultrasound optimization for gene delivery: A key factor achieving nuclear DNA localization. J. Control. Rel. 108, 513 (2005).
92. Z. P. Shen, A. A. Brayman, L. Chen, and C. H. Miao, Ultrasound with microbubbles enhances gene expression of plasmid DNA in the liver via intraportal delivery. Gene Ther. 15, 1147 (2008).
93. R. Suzuki, T. Takizawa, Y. Negishi, N. Utoguchi, and K. Maruyama, Effective gene delivery with liposomal bubbles and ultrasound as novel non-viral system. J. Drug Target. 15, 531 (2007).
94. R. Suzuki, T. Takizawa, Y. Negishi, N. Utoguchi, and K. Maruyama, Effective gene delivery with novel liposomal bubbles and ultrasonic destruction technology. Int. J. Pharm. 354, 49 (2008).
95. J. Zheng, J. Liu, M. Dunne, D. A. Jaffray, and C. Allen, In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm. Res. 24, 1193 (2007).
96. N. Kamaly, T. Kalber, A. Ahmad, M. H. Oliver, P. W. So, A. H. Herlihy, J. D. Bell, M. R. Jorgensen, and A. D. Miller, Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging. Bioconjug. Chem. 19, 118 (2008).
97. W. Cai and X. Chen, Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 49(Suppl 2), 113S (2008).